Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

Conditions:   Neurofibromatosis 2;   Vestibular Schwannoma;   Meningioma;   Ependymoma;   Glioma Intervention:   Drug: Selumetinib Sponsors:   Children's Hospital Medical Center, Cincinnati;   AstraZeneca Not yet recruiting - verified March 2017
Source: - Category: Research Source Type: clinical trials

Related Links:

AbstractNeurofibromatosis type II (NF2) is a tumor predisposition syndrome characterized by the development of distinctive nervous system lesions. NF2 results from loss-of-function alterations in theNF2 gene on chromosome 22, with resultant dysfunction of its protein product merlin. NF2 is most commonly associated with the development of bilateral vestibular schwannomas; however, patients also have a predisposition to development of other tumors including meningiomas, ependymomas, and peripheral, spinal, and cranial nerve schwannomas. Patients may also develop other characteristic manifestations such as ocular lesions, neu...
Source: Acta Neuropathologica - Category: Neurology Source Type: research
CONCLUSION: This is the first case of medulloblastoma occurring in a patient with NF2 and raises the possibility of an association between medulloblastoma and NF2. PMID: 26539318 [PubMed]
Source: Surgical Neurology International - Category: Neurosurgery Tags: Surg Neurol Int Source Type: research
More News: AstraZeneca | Brain Tumor | Children | Ependymoma | Glioma | Men | Neurofibromatosis | Neurology